Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Theravance Biopharma
This is a Phase 3, multi-center, open-label study to evaluate the safety and tolerability of ampreloxetine in subjects with primary autonomic failures (MSA, PD, and PAF) and symptomatic nOH. The study consists of 3 periods: (i) 26-week treatment, (ii) 156-week treatment extension, and (iii) 2-week follow-up.
Age
30–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Completion of Study 0170 and, in the opinion of the Investigator, would benefit from long-term treatment with ampreloxetine.
The subject must be able to understand the nature of the study and must provide written informed consent prior to the conduct of any study procedures (including any changes occurring in the subject's current therapeutic regimen).
You may not be if
Subjects may not be enrolled in another clinical trial.
Psychiatric, neurological, or behavioral disorders that may interfere with the ability of subjects to give informed consent, or interfere with the conduct of the study.
Medical, laboratory, or surgical issues deemed by the Investigator to be clinically significant.
Hypersensitivity to ampreloxetine or the formulation excipients.